scispace - formally typeset
A

Angelino Calderone

Researcher at Université de Montréal

Publications -  89
Citations -  3371

Angelino Calderone is an academic researcher from Université de Montréal. The author has contributed to research in topics: Nestin & Muscle hypertrophy. The author has an hindex of 31, co-authored 84 publications receiving 3189 citations. Previous affiliations of Angelino Calderone include Université du Québec & McGill University.

Papers
More filters
Journal ArticleDOI

Nestin-expressing neural stem cells identified in the scar following myocardial infarction.

TL;DR: The novel observation that neural stem cells were recruited to the infarct region of the damaged rat heart and may contribute in part to nerve fiber growth and subsequent innervation of the scar is highlighted.
Journal ArticleDOI

Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction.

TL;DR: Resveratrol treatment does not improve cardiac remodeling and global hemodynamic function post-MI but does preserve contractile reserve and attenuate ANF and CTGF up-regulation.
Journal ArticleDOI

Antagonism of stromal cell-derived factor-1α reduces infarct size and improves ventricular function after myocardial infarction

TL;DR: Data support the existence of an SDF-1α gradient in the damaged rat myocardium increasing toward the infarct region and highlight the novel observation that AMD3100 antagonism of the SDF -1α/CXCR4 axis reduced scar expansion and improved contractility.
Journal ArticleDOI

Nestin+ cells and healing the infarcted heart

TL;DR: Data demonstrate that diverse populations of nestin(+) cells participate in cardiac wound healing and that nestin protein was induced in a subpopulation of smooth muscle α-actin(+, scar-derived myofibroblasts, and the expression of the intermediate filament protein may provide a proliferative advantage.
Journal ArticleDOI

Long-Term Effects of Nonselective Endothelin A and B Receptor Antagonism in Postinfarction Rat Importance of Timing

TL;DR: The use of the nonselective ETA and ETB receptor antagonist LU results in reduced survival, ventricular dilatation, and dysfunction whether started early or late after MI.